Circulating Fetal Cell (CFC) Capture and Isolation
Isolation of circulating fetal cells (CFCs) from maternal peripheral blood has been a major goal for non-invasive prenatal diagnosis. Up until now, engineering difficulty and ineffective bioreagent and system integration have resulted in inconsistent fetal cell capturing and purity, hampering its long-sought prenatal application and deployment in the commercial setting. Abnova develops and provides GMP bioreagent and system solutions for isolation of CFCs as early as 7 week of gestation, thereby providing access to the complete fetal nuclear genome for genetic analysis via fluorescent in situ hybridization (FISH), microarray, and next generation sequencing (NGS).
CytoQuest™ CR - Circulating Fetal Cell Capture and Isolation
Prenatal Testing vs. Diagnosis
Amniocentesis
Chorionic Villus Sampling (CVS)
Cell-free DNA
Circulating Fetal Cell
Sample
Fetal Cells
Placental Tissues
Mixtures of Fetal and Maternal DNA
Fetal Cells
Coverage
High
High
Low
T13, T18, T21 & Sex
High
Accuracy
High
High
High for T21
High
Timing
16 weeks
10 weeks
>9 weeks
>7 weeks
Invasive
Yes
Yes
No
No
Risks to Fetus
Yes
Yes
No
No
Testing vs. Diagnosis
Diagnosis
Diagnosis
Testing
Diagnosis
CytoQuest™ CR system, SCx™ spiral chamber, HBx™ micromixer, and TCx™ thermal control are trademarks and pending patents of Abnova Corporation.
